Gamma Frequency Stimulation in Individuals With Down Syndrome
NCT: NCT05196984 · RECRUITING
Brief Summary
Down Syndrome (DS) is characterized by an additional copy of chromosome 21, which also increases risk of Alzheimer's Disease (AD). The investigators' lab found a non-invasive way to remove toxic proteins from the brain in AD mouse models. Remarkably, treated mice also have improved memory on behavioral testing. The investigators then translated this non-invasive method, which uses light and sound to stimulate the brain, to be used in mild Alzheimer's patients and cognitively normal adults. The investigators have also translated this research into a vibrating speaker device to study tactile vibration to stimulate the brain as well. For the present study, 30 participants with Down Syndrome and 30 cognitively normal adult controls will be recruited, and the investigators will assess their brain waves with electroencephalogram (EEG) during light, sound, and tactile stimulation. The investigators will also test for safety, feasibility, and cognitive performance before and after a 30-60 minute session of light and sound stimulation to optimize the stimulation devices for use in the DS population.
Frequently Asked Questions
What is Gamma Frequency Stimulation in Individuals With Down Syndrome?
Gamma Frequency Stimulation in Individuals With Down Syndrome is a clinical trial registered under NCT05196984. Current status: RECRUITING.
What is the status of NCT05196984?
The current status of NCT05196984 (Gamma Frequency Stimulation in Individuals With Down Syndrome) is: RECRUITING.
When did Gamma Frequency Stimulation in Individuals With Down Syndrome start?
Gamma Frequency Stimulation in Individuals With Down Syndrome started on 2021-12-06.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.